Karpas Strategies’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $16.5M | Buy |
133,008
+70
| +0.1% | +$9.02K | 5.16% | 4 |
|
|
2024
Q1 | $17.5M | Buy |
132,938
+4
| +0% | +$493 | 5.45% | 4 |
|
|
2023
Q4 | $14.5M | Buy |
132,934
+79
| +0.1% | +$8.2K | 4.79% | 4 |
|
|
2023
Q3 | $13.7M | Sell |
132,855
-1,925
| -1% | -$207K | 5.02% | 4 |
|
|
2023
Q2 | $15.6M | Buy |
134,780
+89
| +0.1% | +$10.1K | 5.25% | 3 |
|
|
2023
Q1 | $14.3M | Buy |
134,691
+73
| +0.1% | +$7.88K | 5.05% | 3 |
|
|
2022
Q4 | $14.9M | Buy |
134,618
+83
| +0.1% | +$8.48K | 5.25% | 4 |
|
|
2022
Q3 | $11.6M | Buy |
134,535
+79
| +0.1% | +$7.05K | 4.4% | 4 |
|
|
2022
Q2 | $12.3M | Buy |
134,456
+86
| +0.1% | +$7.62K | 4.29% | 3 |
|
|
2022
Q1 | $11M | Buy |
134,370
+92
| +0.1% | +$7.25K | 3.48% | 5 |
|
|
2021
Q4 | $10.3M | Hold |
134,278
| – | – | 3.3% | 5 |
|
|
2021
Q3 | $12M | Buy |
134,278
+225
| +0.2% | +$17.1K | 3.95% | 5 |
|
|
2021
Q2 | $10.4M | Sell |
134,053
-6,435
| -5% | -$479K | 3.7% | 5 |
|
|
2021
Q1 | $10.3M | Sell |
140,488
-104
| -0.1% | -$7.67K | 3.91% | 5 |
|
|
2020
Q4 | $11M | Buy |
140,592
+628
| +0.4% | +$48K | 4.3% | 3 |
|
|
2020
Q3 | $11.1M | Hold |
139,964
| – | – | 5.1% | 3 |
|
|
2020
Q2 | $10.3M | Hold |
139,964
| – | – | 4.97% | 3 |
|
|
2020
Q1 | $10.3M | Sell |
139,964
-6,288
| -4% | -$494K | 5.58% | 3 |
|
|
2019
Q4 | $12.7M | Hold |
146,252
| – | – | 4.78% | 3 |
|
|
2019
Q3 | $11.7M | Hold |
146,252
| – | – | 4.75% | 3 |
|
|
2019
Q2 | $11.7M | Hold |
146,252
| – | – | 4.86% | 3 |
|
|
2019
Q1 | $11.6M | Buy |
146,252
+69
| +0% | +$5.16K | 4.9% | 3 |
|
|
2018
Q4 | $10.7M | Hold |
146,183
| – | – | 4.98% | 2 |
|
|
2018
Q3 | $9.89M | Hold |
146,183
| – | – | 4.09% | 5 |
|
|
2018
Q2 | $8.47M | Hold |
146,183
| – | – | 3.67% | 6 |
|
|
2018
Q1 | $7.6M | Buy |
146,183
+104
| +0.1% | +$5.62K | 3.3% | 7 |
|
|
2017
Q4 | $7.84M | Sell |
146,079
-419
| -0.3% | -$23.2K | 3.36% | 7 |
|
|
2017
Q3 | $8.95M | Hold |
146,498
| – | – | 3.93% | 5 |
|
|
2017
Q2 | $8.96M | Hold |
146,498
| – | – | 4.04% | 5 |
|
|
2017
Q1 | $8.88M | Hold |
146,498
| – | – | 4.06% | 5 |
|
|
2016
Q4 | $8.23M | Buy |
146,498
+629
| +0.4% | +$36.8K | 3.88% | 5 |
|
|
2016
Q3 | $8.69M | Hold |
145,869
| – | – | 4.24% | 4 |
|
|
2016
Q2 | $8.02M | Hold |
145,869
| – | – | 4% | 4 |
|
|
2016
Q1 | $7.36M | Hold |
145,869
| – | – | 3.82% | 5 |
|
|
2015
Q4 | $7.35M | Hold |
145,869
| – | – | 3.89% | 5 |
|
|
2015
Q3 | $6.88M | Hold |
145,869
| – | – | 3.8% | 5 |
|
|
2015
Q2 | $7.92M | Sell |
145,869
-105
| -0.1% | -$5.89K | 3.95% | 5 |
|
|
2015
Q1 | $8.01M | Sell |
145,974
-105
| -0.1% | -$5.95K | 3.88% | 5 |
|
|
2014
Q4 | $7.92M | Hold |
146,079
| – | – | 3.8% | 5 |
|
|
2014
Q3 | $8.26M | Hold |
146,079
| – | – | 4.13% | 4 |
|
|
2014
Q2 | $8.06M | Hold |
146,079
| – | – | 4.04% | 3 |
|
|
2014
Q1 | $7.91M | Buy |
146,079
+4,205
| +3% | +$218K | 4.21% | 4 |
|
|
2013
Q4 | $6.78M | Hold |
141,874
| – | – | 3.74% | 4 |
|
|
2013
Q3 | $6.45M | Hold |
141,874
| – | – | 3.78% | 3 |
|
|
2013
Q2 | $6.29M | Buy |
+141,874
| New | +$6.34M | 3.85% | 3 |
|
Other funds holding MRK
Karpas Strategies's MRK Position: Q2 2024 in Review
Karpas Strategies increased its Merck (MRK) stake by 0.05% in Q2 2024, buying an estimated $9.02K and bringing the position to 133,008 shares worth $16.5M. The position accounts for 5.16% of the portfolio, ranked #4.
Karpas Strategies first reported a position in MRK in Q2 2013 and has held it in 45 quarters since. The position peaked at $17.5M in Q1 2024. 3,544 funds tracked by Wall St. Rank hold MRK as of Q2 2024.
- Karpas Strategies held 133,008 shares of Merck worth $16.5M as of Q2 2024.
- Karpas Strategies bought 70 Merck shares in Q2 2024, an estimated $9.02K.
- Merck made up 5.16% of Karpas Strategies's portfolio in Q2 2024, its #4 holding.
- Karpas Strategies first reported a position in Merck in Q2 2013 and has held it in 45 quarters since.
- Karpas Strategies's Merck position peaked at $17.5M in Q1 2024.
- 3,544 funds tracked by Wall St. Rank held Merck as of Q2 2024.
Based on Karpas Strategies's 13F filing for Q2 2024, filed 30 Jul 2024.